Fusion of Epstein-Barr virus nuclear antigen-1-derived glycine-alanine repeat to trans-dominant HIV-1 gag increases inhibitory activities and survival of transduced cells in vivo

Human Gene Therapy

Volumn 19, Issue 6, 2008, Pages 622-634

  Hammer, Diana ^a,b   Wild, Jens ^a   Ludwig, Christine ^a   Asbach, Benedikt ^a   Notka, Frank ^b   Wagner, Ralf ^a,b,c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Geneart AG   (Germany)

^c Institute of Medical Microbiology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; EPSTEIN BARR VIRUS ANTIGEN; GAG PROTEIN; GLYCINE; PROTEASOME;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN STABILITY; VIRUS REPLICATION;

AIDS VACCINES; ALANINE; ANIMALS; CELL LINE; CELL SURVIVAL; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE THERAPY; GLYCINE; HIV INFECTIONS; HIV-1; HUMANS; MICE; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT FUSION PROTEINS; REPETITIVE SEQUENCES, AMINO ACID; TRANSDUCTION, GENETIC; TRANSGENES; VACCINES, DNA; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 46249106228     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.095     Document Type: Article

References (61)

1. Beal, R., Deveraux, Q., Xia, G., Rechsteiner, M., and Pickart, C. (1996). Surface hydrophobic residues of multiubiquitin chains essential for proteolytic targeting. Proc. Natl. Acad. Sci. U.S.A. 93, 861-866.
2. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7, 791-802.
3. Bojak, A., Wild, J., Deml, L., and Wagner, R. (2002a). Impact of codon usage modification on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines. Intervirology 45, 275-286.
4. gag. Vaccine 20, 1980-1984.
5. Bukrinskaya, A.G. (2004). HIV-1 assembly and maturation. Arch. Virol. 149, 1067-1082.
6. Caputo, A., Rossi, C., Bozzini, R., Betti, M., Grossi, M.P., Barbanti-Brodano, G., and Balboni, P.G. (1997). Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication. Gene Ther. 4, 288-295.
7. Chinen, J., Aguilar-Cordova, E., Ng-Tang, D., Lewis, D.E., and Belmont, J.W. (1997). Protection of primary human T cells from HIV infection by Trev: A transdominant fusion gene. Hum. Gene Ther. 8, 861-868.
8. Dantuma, N.P., Heessen, S., Lindsten, K., Jellne, M., and Masucci, M.G. (2000). Inhibition of proteasomal degradation by the Gly-Ala repeat of Epsein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc. Natl. Acad. Sci. U.S.A. 97, 8381-8385.
9. Das, A.T., Brummelkamp, T.R., Westerhout, E.M., Vink, M., Madiredjo, M., Bernards, R., and Berkhout, B. (2004). Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78, 2601-2605.
10. Deml, L., Bojak, A., Steck, S., Graf, M., Wild, J., Schirmbeck, R., Wolf, H., and Wagner, R. (2001). Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J. Virol. 75, 10991-11001.
11. Ding, S.-F., Lombardi, R., Nazari, R., and Joshi, S. (2002). A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy and sense RNAs and trans-dominant negative mutant Gag and Env proteins. Front. Biosci. 7, 15-28.
12. Drosten, C., Panning, M., Drexler, J.F, Hänsel, F., Pedroso, C., Yeats, J., De Souza Luna, L.K., Samuel, M., Liedigk, B., Lippert, U., Stürmer, M., Doerr, H.W., Brites, C. and Preiser, W. (2006). Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5′ long terminal repeat domain. Clin. Chem. 52, 1258-1266.
13. Egelhofer, M., Brandenburg, G., Martinius, H., Schult-Dietrich, P., Melikyan, G., Kunert, R., Baum, C., Choi, I., Alexandrov, A., and von Laer, D. (2004). Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J. Virol. 78, 568-575.
14. Graf, M., Bojak, A., Deml, L., Bieler, K., Wolf, H., and Wagner, R. (2000). Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression. J. Virol. 74, 10822-10826.
15. Griesenbach, U., Boyton, R.J., Somerton, L., Garcia, S.E., Ferrari, S., Owaki, T., Ya-Fen, Z., Geddes, D.M., Hasegawa, M., Altmann, D.M., and Alton, E.W. (2006). Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration to lung. Gene Ther. 13, 449-456.
16. Haubrich, R., McCutchan, J.A., Holdredge, R., Heiner, L., Merritt, J., and Merchant, B. (1995). An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects. Hum. Gene Ther. 6, 941-955.
17. Heessen, S., Leonchiks, A., Issaeva, N., Sharipo, A., Selivanova, G., Masucci, M.G., and Dantuma, N.P. (2002). Functional p53 chimeras containing the Epsein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proc. Natl. Acad. Sci. U.S.A. 99, 1532-1537.
18. Hoyt, M.A., Zich, J., Takeuchi, J., Zhang, M., Govaerts, C., and Coffino, P. (2006). Glycine-alanine repeats impair proper substrate unfolding by the proteasome. EMBO J. 25, 1720-1729.
19. Inubushi, R., Shimano, R., Oshima, Y., Yoshida, K., Kawamura, M., and Adachi, A. (1998). Suppression of HIV replication by dominant negative mutants of HIV-1 [review]. Int. J. Mol. Med. 2, 325-330.
20. Jooss, K., Ertl, H.C., and Wilson, J.M. (1998). Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. 72, 2945-2954.
21. Kay, M.A., Holterman, A.X., Meuse, L., Gown, A., Ochs, H.D., Linsley, P.S., and Wilson, C.B. (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat. Genet. 11, 191-197.
22. Kay, M.A, Glorioso, J.C., and Naldini, L. (2001). Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics [review]. Nat. Med. 7, 33-40.
23. Klenerman, P., and Hill, A. (2005). T cells and viral persistence: Lessons from diverse infections. Nat. Immunol. 6, 873-879.
24. + cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94, 368-371.
25. Kolls, J.K, Lei, D., Odom, G., Nelson, S., Summer, W.R., Gerber, M.A., and Shellito, J.E. (1996). Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum. Gene Ther. 7, 489-497.
26. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P.M., Klein, G., Kurilla, M.G., and Masucci, M.G. (1995). Inhibition of antigen processing by the internal repeat region of the Epsein-Barr virus nuclear antigen-1. Nature 375, 685-688.
27. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A., and Masucci, M.G. (1997). Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epsein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. U.S.A. 94, 12616-12621.
28. Malim, M.H., Bohnlein, S., Fenrick, R., Le, S.Y., Maizel, J.V., and Cullen, B.R. (1989). Functional comparison of the Rev transactivators encoded by different primate immunodeficiency virus species. Proc. Natl. Acad. Sci. U.S.A. 86, 8222-8226.
29. Mammano, F., Ohagen, S., Hoglund, S., and Göttlinger, H.G. (1994). Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J. Virol. 68, 4927-4936.
30. Miller, A.D., Garcia, J.V., von Suhr, N., Lynch, C.M., Wilson, C., AND Eiden, M.V. (1991). Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65, 2220-2224.
31. + T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum. Gene Ther. 16, 1065-1074.
32. Nakamura, Y., Kameoka, M., Tobiume, M., Kaya, M., Ohki, K., Yamada, T., and Ikuta, K. (1997). A chain section containing epitopes for cytotoxic T, B and helper T cells within a highly conserved region found in the human immunodeficiency virus type 1 Gag protein. Vaccine 15, 489-496.
33. Nielsen, M.H., Pedersen, F.S., and Kjems, J. (2005). Molecular strategies to inhibit HIV-1 replication. Retrovirology 2, 10.
34. Ossevoort, M., Visser, B.M., van den Wollenberg, D.J., van der Voort, E.I., Offringa, R., Melief, C.J., Toes, R.E., and Hoeben, R.C. (2003). Creation of immune "stealth" genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther. 10, 2020-2028.
35. Ossevoort, M., Zaldumbide, A., Cramer, S.J., van der Voort, E.I., Toes, R.E., and Hoeben, R.C. (2006). Characterization of an immuno "stealth" derivative of the herpes simplex virus thymidine-kinase gene. Cancer Gene Ther. 13, 584-591.
36. Ranga, U., Woffendin, C., Verma, S., Xu, L., June, C.H., Bishop, D.K., and Nabel, G.J. (1998). Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc. Natl. Acad. Sci. U.S.A. 95, 1201-1206.
37. Ratner, L., Fisher, A., Jagodzinski, L.L., Mitsuya, H., Liou, R.S., Gallo, R.C., and Wong-Staal, F. (1987). Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses 3, 57-69.
38. Rickinson, A.B., and Moss, D.J. (1997). Human cytotoxic T lymphocyte responses to Epsein-Barr virus infection [review]. Annu. Rev. Immunol. 15, 405-431.
39. Rübsamen-Waigmann, H., Willems, W.R., Bertram, U., and von Briesen, H. (1989). Reversal of HIV-phenotype to fulminant replication on macrophages in perinatal transmission. Lancet 2, 1155-1156.
40. Sharipo, A., Imreh, M., Leonchiks, A., Imreh, S., and Masucci, M.G. (1998). A minimal glycine-alanine repeat prevents the interaction of ubiquitinated IκBα with the proteasome: A new mechanism for selective inhibition of proteolysis. Nat. Med. 4, 939-944.
41. Sharipo, A., Imreh, M., Leonchiks, A., Branden, C., and Masucci, M.G. (2001). Cis-inhibition of proteasomal degradation by viral repeats: Impact of length and amino acid composition. FEBS Lett. 499, 137-142.
42. Shimano, R., Iida, S., Fukumori, T., Yamamoto, Y., Kawamura, M., Furuta, R.A., and Adachi, A. (1998). Inhibition of HIV replication by capsid mutant C6b. Biochem. Biophys. Res. Commun. 242, 313-316.
43. Smythe, J.A., Sun, D., Thomson, M., Markham, P.D., Reitz, M.S., Jr., Gallo, R.C., and Lisziewicz, J. (1994). A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 91, 3657-3661.
44. Spearman, P., Wang, J.J., Vander Heyden, N., and Ratner, L. (1994). Identification of human immunodeficiency virus type 1 Gag domains essential to membrane binding and particle assembly. J. Virol. 68, 3232-3242.
45. Strayer, D.S., Akkina, R., Bunnell, B.A., Dropulic, B., Planelles, V., Pomerantz, R.J., Rossi, J.J., and Zaia, J.A. (2005). Current status of gene therapy strategies to treat HIV/AIDS. Mol. Ther. 11, 823-842.
46. Tang, J.W., and Pillay, D. (2004). Transmission of HIV-1 drug resistance [review]. J. Clin. Virol. 30, 1-10.
47. + T cell recognition. J. Biol. Chem. 276, 33353-33360.
48. + T cell epitopes from Epsein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 199, 1421-1431.
49. + T cell epitopes. J. Exp. Med. 204, 525-532.
50. Trono, D., Feinberg, M.B., and Baltimore, D. (1989). HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59, 113-120.
51. von Laer, D. and Brandenburg, G. (2001). Gene Therapy for HIV infection by intracellular immunisation with antiviral genes. AIDS Rev. 3, 169-177.
52. von Laer, D., Hasselmann, S., and Hasselmann, K. (2006). Impact of gene-modified T cells on HIV infection dynamics. J. Theor. Biol. 238, 60-77.
53. von Poblotzki, A., Wagner, R., Niedrig, M., Wanner, G., Wolf, H., and Modrow, S. (1993). Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation. Virology 193, 981-985.
54. + T lymphocytes. J. Exp. Med. 199, 459-470.
55. Wagner, R., Böltz, T., Deml, L., Modrow, S., and Wolf, H. (1993). Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses. J. Gen. Virol. 74, 1261-1269.
56. Wagner, R., Deml, L., Fliessbach, H., Wanner, G., and Wolf, H. (1994). Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology 200, 162-175.
57. Woffendin, C., Ranga, U., Yang, Z., Xu, L., and Nabel, G.J. (1996). Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc. Natl. Acad. Sci. U.S.A. 93, 2889-2894.
58. Yang, Y., Jooss, K.U., Su, Q., Ertl, H.C., and Wilson, J.M. (1996). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3, 137-144.
59. Yewdell, J.W. (2003). Immunology: hide and seek in the peptidome. Science 301, 1334-1335.
60. Yin, Y., Manoury, B., and Fahraeus, R. (2003). Self-inhibition of synthesis and antigen presentation by Epsein-Barr virus-encoded EBNA1. Science 301, 1371-1374.
61. Zhang, M., and Coffino, P. (2004). Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing. J. Biol. Chem. 279, 8635-8641.